Patents by Inventor David E. KANG

David E. KANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of beta-arrestin oligomerization in tauopathy
    Patent number: 11896644
    Abstract: As disclosed herein, ?-arrestin1 and ?-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both ?-arrestin1 and ?-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when ?-arrestin2 is overexpressed, tau levels become elevated. The data indicate that ?-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of ?-arrestin2. Therefore, disclosed herein are ?-arrestin oligomerization inhibitors that can be used to prevent ?-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a ?-arrestin oligomerization inhibitor disclosed herein.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: February 13, 2024
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jung A. Woo, Stephen Bryant Liggett, David E. Kang, Yu Chen, Eric Lewandowski
  • INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY
    Publication number: 20230116783
    Abstract: As disclosed herein, ?-arrestin1 and ?-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both ?-arrestin1 and ?-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when ?-arrestin2 is overexpressed, tau levels become elevated. The data indicate that ?-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of ?-arrestin2. Therefore, disclosed herein are ?-arrestin oligomerization inhibitors that can be used to prevent ?-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a ?-arrestin oligomerization inhibitor disclosed herein.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 13, 2023
    Inventors: Jung A. WOO, Stephen Bryant LIGGETT, David E. KANG, Yu CHEN, Eric LEWANDOWSKI